Non-steroidal Anti-inflammatory Drugs Market (By Disease Indication: Arthritis, Migraine, Ophthalmic Diseases; By Route Of Administration: Oral, Topical; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Non-steroidal Anti-inflammatory Drugs Market 

5.1. COVID-19 Landscape: Non-steroidal Anti-inflammatory Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Non-steroidal Anti-inflammatory Drugs Market, By Disease Indication

8.1. Non-steroidal Anti-inflammatory Drugs Market, by Disease Indication, 2022-2030

8.1.1 Arthritis

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Migraine

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Ophthalmic Diseases

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Others

8.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Non-steroidal Anti-inflammatory Drugs Market, By Route of Administration

9.1. Non-steroidal Anti-inflammatory Drugs Market, by Route of Administration, 2022-2030

9.1.1. Oral

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Topical

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Others

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Non-steroidal Anti-inflammatory Drugs Market, By Distribution Channel 

10.1. Non-steroidal Anti-inflammatory Drugs Market, by Distribution Channel, 2022-2030

10.1.1. Hospital Pharmacy

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail Pharmacy

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Online Pharmacy

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Non-steroidal Anti-inflammatory Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.1.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.2.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.3.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.6.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.4.7.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.4.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Disease Indication (2017-2030)

11.5.5.2. Market Revenue and Forecast, by Route of Administration (2017-2030)

11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

Chapter 12. Company Profiles

12.1. Pfizer Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Bayer AG

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. GSK plc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Dr. Reddy’s Laboratories Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Viatris Inc

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Teva Pharmaceutical Industries Ltd.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Johnson And Johnson Services, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Merck & Co., Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms